Mitchell Capital Management Co. Acquires Shares of 9,297 Icon Plc $ICLR

Mitchell Capital Management Co. bought a new position in shares of Icon Plc (NASDAQ:ICLR) in the 3rd quarter, Holdings Channel.com reports. The institutional investor bought 9,297 shares of the medical research company’s stock, valued at approximately $1,627,000.

A number of other large investors have also added to or reduced their stakes in the business. Geneos Wealth Management Inc. boosted its position in Icon by 11.5% during the second quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after purchasing an additional 56 shares during the period. Spire Wealth Management lifted its stake in shares of Icon by 10.1% during the 3rd quarter. Spire Wealth Management now owns 678 shares of the medical research company’s stock worth $119,000 after buying an additional 62 shares during the last quarter. Mutual Advisors LLC lifted its stake in shares of Icon by 3.6% during the 2nd quarter. Mutual Advisors LLC now owns 2,698 shares of the medical research company’s stock worth $392,000 after buying an additional 93 shares during the last quarter. Private Trust Co. NA boosted its holdings in shares of Icon by 200.0% during the 3rd quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after buying an additional 94 shares during the period. Finally, Sierra Legacy Group grew its stake in Icon by 2.5% in the 3rd quarter. Sierra Legacy Group now owns 4,540 shares of the medical research company’s stock valued at $794,000 after buying an additional 110 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Weiss Ratings restated a “hold (c)” rating on shares of Icon in a report on Monday, December 29th. BMO Capital Markets started coverage on Icon in a research note on Thursday, November 13th. They issued a “market perform” rating and a $175.00 price target for the company. Mizuho set a $216.00 price objective on Icon in a research report on Friday, January 9th. TD Cowen lifted their target price on Icon from $172.00 to $183.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Finally, Robert W. Baird set a $217.00 price target on shares of Icon in a research note on Friday, January 9th. Six analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $200.60.

Icon Price Performance

Shares of NASDAQ:ICLR opened at $133.14 on Thursday. The company has a market cap of $10.75 billion, a price-to-earnings ratio of 18.02, a PEG ratio of 3.03 and a beta of 1.27. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. The firm has a 50 day simple moving average of $179.90 and a 200 day simple moving average of $176.28. Icon Plc has a one year low of $125.10 and a one year high of $211.00.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.